Starling Oncology, Inc.
STLNW- Exchange
- Nasdaq
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $163.5K in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Starling Oncology, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 22 | 14 | −8 |
| Shares | 2.75M | 3.32M | +576.1K (+21.0%) |
| Value | $2.56M | $3.90M | +$1.33M (+52.1%) |
New holders (0)
Institutions that held Starling Oncology, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
None.
Sold out (8)
Institutions that held Starling Oncology, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Bulldog Investors, LLP | 75,267 | $52.0K |
| Park West Asset Management LLC | 62,200 | $43.0K |
| Greenhaven Road Investment Management, L.P. | 47,003 | $32.0K |
| HBK Investments L P | 14,000 | $10.0K |
| CSS LLC | 14,136 | $10.0K |
| DuPont Capital Management Corp | 12,500 | $9.00K |
| Virtu Financial LLC | 12,603 | $9.00K |
| Captrust Financial Advisors | 3,957 | $3.00K |